Search

Search Constraints

You searched for: Author/Creator Lalovic, Bojan

Search Results

3. Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant. Issue 6 (17th January 2021)

5. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Issue 10080 (29th April 2017)

9. Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. Issue 4 (23rd November 2021)